| - Recent Results:
-
- Over the last two years, RW Malone MD, LLC has worked intelligently as well as relentlessly to help our clients win over 100 million worth of grants and contracts. That is success we can all be proud of!
-
- Chairpson and reviewer for NIH/NAIAD Committee on Partnerships in Biodefense Immunotherapeutics, Fall 2011. Robert W Malone, MD, MS
-
- Committee member and reviewer for NIH/NAIAD Committee for Development of Technologies that Accelerate the Immune Response to BioDefense Vaccines., Fall 2011. Robert W Malone, MD, MS
-
- 12-14 July 2011 - The World Health Organization (WHO) hosted the second Consultation on the Global Action Plan for Influenza Vaccines. Invited speaker: Robert W Malone, MD, MS "Vaccine Production Strategies: Ensuring Alignment and Sustainability"
-
- Successful submission and funding of a 80 million US government contract to a biotechnology client in 2011 -proposal manager and chief scienctific writer (press release in progress).
-
- Succesful submission of three white papers to a government agency in 2011: one contract was funded, one is still being considered.
-
- Medical Director, Vaccines, under contract and consultant with Beardsworth 2009 - present (see press release)
- .
- Provided significant technical due-diligence for a fortune 500 company pursuing infectious disease opportunities in the fall of 2009.
-
- Proposal manager and editor for URI and Epivax's funded submission of U19 grant for $13 million from the National Institutes of Health to pioneer the development and application of an integrated gene-to-vaccine program targeting emerging infectious diseases. 2009.
-
- Medical director under contract and consultant with Accelovance 2008-2009. While in this position, Accelovance was awarded the title of "Best Contract Research Organization" (CRO) award at the 2009 World Vaccine Congress.
-
- Author, editor and capture manager for Accelovance of funded $3 million CDC contract for influenza vaccine immunogenicity clinical trial.
-
- Proposal manager and editor for Chesapeake PERL's funded submission and funding in October 2009 of the US Army SBIR Grant Year II: Commercialization Pilot Program (CPP), Improved Protein Manufacturing in Insect Expression System - Develop HIV-1 Envelope Proteins as HIV Vaccine Antigen
-
- Proposal manager and editor for Chesapeake PERL's funded submission and funding in June 2009 of the Department of Energy SBIR Grant Phase II: Identification, Production and Characterization of Novel Lignase Proteins from Termite for Depolymerization of Lignocellulose.
-
- Adjunct professor, Kennesaw University 2009- present.
-
- Public health survey of experts for a large pharmaceutical corporation, regarding governmental vaccination strategies. 2009
-
- Scientific Advisory Board member of a mid-sized biotechnology company. 2006 -to present)
-
- Member, NIH Committee for Biodefense Vaccine Enhancement, 2008.
-
- Public health survey of experts for a large pharmaceutical corporation, regarding governmental vaccination strategies. 2008
-
- Protocol Author and Clinical Director of a large Influenza Phase 1 Clinical Trial: FDA had no revisions on intial IND review. 2007
-
- Proposal manager and editor of a funded submission of an influenza Contract through HHS: total budget 130 million. 2006
-
- Successful submission of a CDC foundation award for TB: total budget one million.
-
- Provided due diligence for a large financial institution involving venture capital for significant late-stage biotechnology investment.
-
-
-
-
| |
